Works by Lu, Yumeng


Results: 16
    1
    2
    3
    4
    5
    6

    Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma.

    Published in:
    Journal of Biomedical Science, 2022, v. 29, n. 1, p. 1, doi. 10.1186/s12929-022-00813-2
    By:
    • Xie, Yongsheng;
    • Wang, Yingcong;
    • Xu, Zhijian;
    • Lu, Yumeng;
    • Song, Dongliang;
    • Gao, Lu;
    • Yu, Dandan;
    • Li, Bo;
    • Chen, Gege;
    • Zhang, Hui;
    • Feng, Qilin;
    • Zhang, Yong;
    • Hu, Ke;
    • Huang, Cheng;
    • Peng, Yu;
    • Wu, Xiaosong;
    • Mao, Zhiyong;
    • Shao, Jimin;
    • Zhu, Weiliang;
    • Shi, Jumei
    Publication type:
    Article
    7

    Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma.

    Published in:
    Journal of Biomedical Science, 2022, v. 29, n. 1, p. 1, doi. 10.1186/s12929-022-00813-2
    By:
    • Xie, Yongsheng;
    • Wang, Yingcong;
    • Xu, Zhijian;
    • Lu, Yumeng;
    • Song, Dongliang;
    • Gao, Lu;
    • Yu, Dandan;
    • Li, Bo;
    • Chen, Gege;
    • Zhang, Hui;
    • Feng, Qilin;
    • Zhang, Yong;
    • Hu, Ke;
    • Huang, Cheng;
    • Peng, Yu;
    • Wu, Xiaosong;
    • Mao, Zhiyong;
    • Shao, Jimin;
    • Zhu, Weiliang;
    • Shi, Jumei
    Publication type:
    Article
    8
    9

    Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation.

    Published in:
    Acta Biochimica et Biophysica Sinica, 2023, v. 55, n. 12, p. 1884, doi. 10.3724/abbs.2023260
    By:
    • Shuhan Jin;
    • Bo Li;
    • Bibo Zhang;
    • Xuejie Gao;
    • Xinyan Jia;
    • Li Xu;
    • Shuaikang Chang;
    • Ke Hu;
    • Guanli Wang;
    • Zhijian Xu;
    • Ting Zhang;
    • Dongliang Song;
    • Guang Yang;
    • Xiaosong Wu;
    • Huabin Zhu;
    • Cheng Huang;
    • Yumeng Lu;
    • Jumei Shi;
    • Weiliang Zhu;
    • Gege Chen
    Publication type:
    Article
    10
    11

    A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe.

    Published in:
    Journal of Experimental & Clinical Cancer Research (17569966), 2020, v. 39, n. 1, p. 1, doi. 10.1186/s13046-020-01597-9
    By:
    • Hu, Liangning;
    • Li, Bo;
    • Chen, Gege;
    • Song, Dongliang;
    • Xu, Zhijian;
    • Gao, Lu;
    • Xi, Mengyu;
    • Zhou, Jinfeng;
    • Li, Liping;
    • Zhang, Hui;
    • Feng, Qilin;
    • Wang, Yingcong;
    • Lu, Kang;
    • Lu, Yumeng;
    • Bu, Wenxuan;
    • Wang, Houcai;
    • Wu, Xiaosong;
    • Zhu, Weiliang;
    • Shi, Jumei
    Publication type:
    Article
    12
    13
    14
    15
    16